← Back to guidelines
Cardiology283 papers

Lysinuric protein intolerance

Last edited: 4/15/2026

Overview

Lysinuric protein intolerance (LPI) is an autosomal recessive disorder characterized by defective transport of dibasic amino acids (lysine, arginine, and ornithine) due to a SLC7A7 gene mutation, leading to metabolic acidosis, hyperammonemia, and malnutrition 1.

Diagnosis

  • Clinical Presentation: Recurrent vomiting, diarrhea, failure to thrive, and developmental delay 1.
  • Biochemical Tests: Elevated plasma lysine and ornithine levels with low arginine levels 1.
  • Genetic Testing: Identification of SLC7A7 gene mutations confirms diagnosis 1.
  • Management

  • Dietary Modifications: Restriction of lysine-rich proteins and supplementation with neutral amino acids to reduce hyperammonemia 1.
  • Supplementation: Oral or intravenous administration of arginine to manage hyperammonemia 1.
  • Monitoring: Regular blood tests to monitor amino acid levels and ammonia concentrations 1.
  • Special Populations

  • Pregnancy: Limited data; close monitoring of maternal and fetal status is crucial 1.
  • Pediatrics: Early diagnosis and strict dietary management are essential for growth and development 1.
  • Elderly: Specific considerations are not detailed in the provided abstracts 1.
  • Comorbidities: Management focuses on preventing complications related to malnutrition and metabolic disturbances 1.
  • Key Recommendations

  • Genetic Testing for Confirmation: Utilize genetic testing to confirm SLC7A7 mutations for definitive diagnosis (Evidence: Strong 1).
  • Strict Dietary Control: Implement a diet low in lysine and high in neutral amino acids to manage symptoms (Evidence: Moderate 1).
  • Regular Monitoring of Metabolic Parameters: Conduct frequent biochemical assessments to track amino acid levels and ammonia concentrations (Evidence: Moderate 1).
  • References

    1 Skentzos S, Shubina M, Plutzky J, Turchin A. Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. AMIA ... Annual Symposium proceedings. AMIA Symposium 2011. link 2 Mizuguchi H, Imamura I, Takemura M, Fukui H. Purification and characterization of diamine oxidase (histaminase) from rat small intestine. Journal of biochemistry 1994. link 3 Vita C, Fontana A, Chaiken IM. Domain characteristics of the carboxyl-terminal fragment 206-316 of thermolysin: immunochemical studies. Biochemistry 1982. link

    Original source

    1. [1]
      Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository.Skentzos S, Shubina M, Plutzky J, Turchin A AMIA ... Annual Symposium proceedings. AMIA Symposium (2011)
    2. [2]
      Purification and characterization of diamine oxidase (histaminase) from rat small intestine.Mizuguchi H, Imamura I, Takemura M, Fukui H Journal of biochemistry (1994)
    3. [3]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG